GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022

3 years ago

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it…

Simply Better Brands Corp. Announces Execution of Non-Binding Term Sheet to Acquire CFH Limited, a Seed-To-Shelf CBD Manufacturer, to Support Accelerated Growth

3 years ago

Acquisition enables expanded vertical integration, research-driven innovation and cost synergies on the PureKana Wellness BrandVANCOUVER, British Columbia, April 27, 2022…

ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone

3 years ago

Oral Session Demonstrates CF-370’s Potent Activity in a Rabbit Pneumonia Model of an Extensively-Resistant Pseudomonas aeruginosa InfectionYONKERS, N.Y., April 27,…

InnerScope Hearing Technologies (OTC: INND) Launches New eCommerce Website with the Rebranding of iHEAR Direct-to-Consumer Hearing Aids

3 years ago

The New Relaunch of iHEARdirect.com Website Includes: Enhanced Customer FeaturesFree Online Hearing ScreeningHearing Aid & Hearing Loss Information BlogSeries of…

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time

3 years ago

RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers…

Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines

3 years ago

– Series B Financing led by Huadong Medicine Investment Holding Co., Ltd, with participation from Natural Capital Investment Fund, Plum…

Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

3 years ago

Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to…

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

3 years ago

New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by NightHawkDURHAM, N.C., April 27,…

Theratechnologies to Focus Its Commercialization Activities on the North American Territory

3 years ago

MONTREAL, April 27, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused…

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy

3 years ago

- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based…